Literature DB >> 2810583

Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported.

D A Evans1, H H Funkenstein, M S Albert, P A Scherr, N R Cook, M J Chown, L E Hebert, C H Hennekens, J O Taylor.   

Abstract

Clinically diagnosed Alzheimer's disease and other dementing illnesses were assessed in a geographically defined US community. Of 3623 persons (80.8% of all community residents over 65 years of age) who had brief memory testing in their homes, a stratified sample of 467 persons underwent neurological, neuropsychological, and laboratory examination. Prevalence rates of Alzheimer's disease were calculated for the community population from the sample undergoing clinical evaluation. Of those over the age of 65 years, an estimated 10.3% (95% confidence limits, 8.1% and 12.5%) had probable Alzheimer's disease. This prevalence rate was strongly associated with age. Of those 65 to 74 years old, 3.0% (95% confidence limits, 0.8 and 5.2) had probable Alzheimer's disease, compared with 18.7% (95% confidence limits, 13.2 and 24.2) of those 75 to 84 years old and 47.2% (95% confidence limits, 37.0 and 63.2) of those over 85 years. Other dementing conditions were uncommon. Of community residents with moderate or severe cognitive impairment, 84.1% had clinically diagnosed Alzheimer's disease as the only probable diagnosis. These data suggest that clinically diagnosed Alzheimer's disease is a common condition and that its public health impact will continue to increase with increasing longevity of the population.

Entities:  

Mesh:

Year:  1989        PMID: 2810583

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  351 in total

Review 1.  Health care rationing in the aged: ethical and clinical perspectives.

Authors:  E G Howe; C J Lettieri
Journal:  Drugs Aging       Date:  1999-07       Impact factor: 3.923

2.  Update on Alzheimer's disease: recent findings and treatments.

Authors:  R O'Hara; M S Mumenthaler; J A Yesavage
Journal:  West J Med       Date:  2000-02

Review 3.  Behavioural problems associated with dementia: the role of newer antipsychotics.

Authors:  G Stoppe; C A Brandt; J H Staedt
Journal:  Drugs Aging       Date:  1999-01       Impact factor: 3.923

Review 4.  Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience.

Authors:  Sandra S Kindermann; Christian R Dolder; Anne Bailey; Ira R Katz; Dilip V Jeste
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

5.  Tacrine for Alzheimer's disease. Costs and benefits.

Authors:  D Knopman
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

Review 6.  Patterns of compensation and vulnerability in normal subjects at risk of Alzheimer's disease.

Authors:  Oscar L Lopez; James T Becker; Lewis H Kuller
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

7.  Incidence and risk factors for cognitive impairment no dementia and mild cognitive impairment in African Americans.

Authors:  Frederick W Unverzagt; Adesola Ogunniyi; Vanessa Taler; Sujuan Gao; Kathleen A Lane; Olusegun Baiyewu; Oye Gureje; Valerie Smith-Gamble; Ann Hake; Hugh C Hendrie; Kathleen S Hall
Journal:  Alzheimer Dis Assoc Disord       Date:  2011 Jan-Mar       Impact factor: 2.703

8.  A longitudinal study of drinking and cognitive performance in elderly Japanese American men: the Honolulu-Asia Aging Study.

Authors:  D J Galanis; C Joseph; K H Masaki; H Petrovitch; G W Ross; L White
Journal:  Am J Public Health       Date:  2000-08       Impact factor: 9.308

9.  Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals.

Authors:  Jason J Corneveaux; Amanda J Myers; April N Allen; Jeremy J Pruzin; Manuel Ramirez; Anzhelika Engel; Michael A Nalls; Kewei Chen; Wendy Lee; Kendria Chewning; Stephen E Villa; Hunsar B Meechoovet; Jill D Gerber; Danielle Frost; Hollie L Benson; Sean O'Reilly; Lori B Chibnik; Joshua M Shulman; Andrew B Singleton; David W Craig; Kendall R Van Keuren-Jensen; Travis Dunckley; David A Bennett; Philip L De Jager; Christopher Heward; John Hardy; Eric M Reiman; Matthew J Huentelman
Journal:  Hum Mol Genet       Date:  2010-06-09       Impact factor: 6.150

Review 10.  Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.

Authors:  Greg L Plosker; Katherine A Lyseng-Williamson
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.